| ORKA |
ORUKA THERAPEUTICS, INC. |
Common Stock, $0.001 par value |
20% |
$161,971,372 |
+$38,464,806 |
11,162,741 |
+31% |
Fairmount Funds Management LLC |
17 Sep 2025 |
| JBIO |
Jade Biosciences, Inc. |
Common Stock, $0.0001 par value |
20% |
$89,373,614 |
+$26,797,898 |
10,353,875 |
+43% |
Fairmount Funds Management LLC |
06 Oct 2025 |
| GLTO |
Galecto, Inc. |
Common Stock, par value par value $0.00001 per share |
20% |
$2,965,590 |
|
397,000 |
|
Fairmount Funds Management LLC |
10 Nov 2025 |
| CBIO |
Crescent Biopharma, Inc. |
Ordinary Shares, $0.001 par value |
19% |
$85,103,709 |
+$37,990,471 |
5,643,482 |
+81% |
Fairmount Funds Management LLC |
04 Dec 2025 |
| VRDN |
Viridian Therapeutics, Inc.\DE |
Common Stock, $0.01 par value |
15% |
$345,826,621 |
|
16,025,330 |
|
Fairmount Funds Management LLC |
23 Oct 2025 |
| APGE |
Apogee Therapeutics, Inc. |
Common Stock, $0.00001 par value |
10% |
$456,430,807 |
+$20,390,674 |
6,047,027 |
+4.7% |
Peter Evan Harwin |
22 Jan 2026 |
| SYRE |
SPYRE THERAPEUTICS, INC. |
Common Stock, $0.0001 par value |
10% |
$136,033,480 |
|
8,106,882 |
|
Peter Evan Harwin |
15 Oct 2025 |
| COGT |
Cogent Biosciences, Inc. |
Common Stock, $0.001 par value |
9.9% |
$577,623,327 |
+$13,657,440 |
16,261,918 |
+2.4% |
Fairmount Funds Management LLC |
22 Jan 2026 |
| IKT |
Inhibikase Therapeutics, Inc. |
Common Stock, par value $0.001 per share |
9.9% |
$15,300,494 |
|
7,018,575 |
|
Fairmount Funds Management LLC |
31 Dec 2024 |
| ELVN |
ENLIVEN THERAPEUTICS, INC. |
Common Stock, par value $0.001 per share |
6.3% |
$76,752,662 |
+$10,518,799 |
3,711,444 |
+16% |
Fairmount Funds Management LLC |
30 Jun 2025 |
| DNTH |
DIANTHUS THERAPEUTICS, INC. |
Common Stock, $0.001 par value |
4.9% |
$72,191,285 |
-$64,524,950 |
2,139,635 |
-47% |
Fairmount Funds Management LLC |
21 Nov 2025 |
| ATXS |
Astria Therapeutics, Inc. |
Common Stock, par value $0.001 per share |
4% |
$17,304,917 |
-$25,421,673 |
2,377,049 |
-59% |
Fairmount Funds Management LLC |
14 Oct 2025 |
| KNSA |
Kiniksa Pharmaceuticals International, plc |
Class A Ordinary Shares, nominal value $0.000273235 per share |
0% |
$0 |
|
0 |
|
Fairmount Funds Management LLC |
31 Dec 2024 |
| ANAB |
ANAPTYSBIO, INC. |
Common Stock, par value $0.001 per share |
0% |
$0 |
-$28,699,380 |
0 |
-100% |
Fairmount Funds Management LLC |
31 Dec 2024 |